Clinical application advancement of pulmonary surfactant

Abstract

Abstract: Pulmonary surfactant is a type of a phospholipid - protein complexes synthesized by II alveolar epithelial cells. It has many functions as decreasing alveolar surface tension to maintain alveolar stability, reducing alveolar fluid extravasation in the prevention of pulmonary edema, promoting the clearance of inlet ability, inhibiting bronchoconstriction and increasing the pulmonary immune function, reducing the inflammation and improving the lung anti-infection. The natural and synthetic surfactant preparations have some therapeutic effects on the clinical treatment of primary pulmonary surfactant deficiency disease and various secondary pulmonary surfactant-related diseases through tracheal injection or inhalation.

Key words: Pulmonary surfactant(PS), Respiratory distress syndrome(RDS), Meconium aspiration syndrome(MAS)

CLC Number:

XU Guo-cheng, LI Zhi-qi. Clinical application advancement of pulmonary surfactant[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 832-835.

References

[1] Cole FS, Nogee LM, Hamvas A. Defects in surfactant synthesis: clinical implications [J]. Pediatr Clin North Am,2006,53(5):911-927.
[2] Halliday HL. Surfactants:past, present and future[J]. J Perinatol,2008,28 Suppl 1:S47-S56.
[3] Hane F, Moores B, Amrein M, et al. Effect of SP-C on surface potential distribution in pulmonary surfactant: Atomic force microscopy and Kelvin probe force microscopy study[J]. Ultramicroscopy,2009,109(8):968-973.
[4] Dahl M, Holmskov U, Husby S, et al. Surfactant protein D levels in umbilical cord blood and capillary blood of premature infants. The influence of perinatal factors[J]. Pediatr Res,2006,59(6):806-810.
[5] Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn.Surfactant-replacement therapy for respiratory distress in the preterm and term neonate [J]. Pediatrics, 2008,121(2):419-432.
[6] Cogo PE, Zimmermann LJ, Pesavento R, et al. Surfactant kinetics in preterm infants on mechanical ventilation who did and did not develop broncho pulmonary dysplasia[J]. Crit Care Med, 2003, 31(5):1532-1538.
[7] Minowa H, Takahashi Y, Kawaguchi C, et al. Expression of intrapulmonary surfactant apoprotein-A in autopsied Lungs: comparative study of cases with or without pulmonary hypoplasia[J]. Pediatr Res, 2000,48(5):674-678.
[8] Halliday HL. Recent clinical trials of surfactant treatment for neonates[J]. Biol Neonate, 2006,89(4):323-329.
[9] 新生儿呼吸疾病研究协作组.猪肺表面活性物质治疗胎粪吸入综合征的多中心随机对照研究[J].中华儿科杂志,2005,43(5):354-359.
[10] 吴丽燕.不同方式注入肺表面活性物质的疗效观察[J].现代医院,2009,1(9):24-26.
[11] Amizuka T, Shimizu H, Niida Y,et al. Surfactants therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema[J].Eur J Pediatr,2003,162(10):697-702.
[12] 戴芸佳.肺泡表面活性物质治疗新生儿呼吸窘迫综合征[J].中国新生儿科杂志,2007,22(3):172-173.
[13] 林静. 肺泡表面活性物质预防和治疗新生儿呼吸窘迫综合征疗效评价[J]. 中国热带医学,2004,4(6):1017-1019.
[14] 刘秀香,肖昕,熊爱华,等.合成及天然肺表面活性剂治疗新生儿呼吸窘迫综合征效果和安全性的Meta分析[J].临床儿科杂志,2004,22 (9):630-632.
[15] Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. [J]. Pediatrics, 2008,121(5):e1310-1318.
[16] 杨杰,宁岑,覃安志,等.早产儿转运前应用肺表面活性物质的临床意义探讨[J]. 中国围产医学杂志,2006,9(1):28-31.
[17] 毕仲江,解福平,周伯香.肺表面活性物质预防新生儿呼吸窘迫综合症[J].南华大学学报,2008,36(4):530-531.
[18] Kakinuma R, Shimizu H, Ogawa Y.Effect of meconium on the rate of in vitro subtype conversion of swine pulmonary surfactant [J].Eur J Pediatr, 2002,161(1):1-36.
[19] Stevens TP, Sinkin RA. Surfactant replacement therapy [J].Chest,2007,131(5):1577-1582.
[20] Lacaze-Masmonteil T. Expanded Use of Surfactant Therapy in newborns[J]. Clin Perinatol, 2007,34(1):179-189.
[21] Been JV, Zimmermann LJ. What is new in surfactant.A clinical view on recent developments in neonatology and paediatrics [J].Eur J Pediatr,2007,166(9):889-899.
[22] 蔡及明,杨艳敏.应用外源性肺泡表面活性物质治疗小儿肺损伤的进展[J].上海医学,2004,27(8):618-620.